Cerebral Edema in Lecanemab Treatment for Alzheimer’s Disease: A Comprehensive Review of Mechanisms, Risk Factors, Imaging, and Management

Abstract

Lecanemab, a monoclonal antibody targeting amyloid-beta protofibrils, has emerged as a promising disease-modifying therapy for early Alzheimer’s disease (AD). However, its use is associated with amyloid-related imaging abnormalities (ARIA), particularly ARIA-E (edema), which presents a significant clinical challenge. This report provides a comprehensive review of cerebral edema in the context of lecanemab treatment, encompassing its pathophysiology, distinguishing features, risk factors, advanced imaging techniques for early detection, and evolving management strategies. We delve into the nuances of vasogenic and cytotoxic edema, explore the complex interplay between amyloid plaque reduction and edema formation, and critically assess the role of genetic predispositions, cerebrovascular disease, and APOE ε4 status. Furthermore, we examine the utility of advanced MRI modalities, including diffusion tensor imaging and permeability mapping, in early ARIA-E detection. Finally, we discuss current management protocols, including treatment interruption, corticosteroid administration, and the potential for individualized therapeutic approaches, highlighting the need for ongoing research to optimize patient safety and maximize the benefits of lecanemab in AD.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction

Alzheimer’s disease (AD) represents a global healthcare crisis, characterized by progressive cognitive decline and neurodegeneration. The amyloid cascade hypothesis, positing that amyloid-beta (Aβ) accumulation drives the pathogenesis of AD, has been a central focus of therapeutic development. Lecanemab, a humanized IgG1 monoclonal antibody, selectively binds to soluble Aβ protofibrils, accelerating their clearance from the brain and demonstrating modest clinical benefit in slowing cognitive decline in early AD patients. However, the advent of amyloid-targeting therapies like lecanemab has brought to the forefront the significant concern of amyloid-related imaging abnormalities (ARIA), specifically ARIA-E (edema) and ARIA-H (microhemorrhages and hemosiderosis). ARIA-E, manifested as vasogenic edema on MRI, poses a significant clinical challenge, necessitating careful monitoring, potential treatment interruption, and, in some cases, symptomatic management. Understanding the mechanisms underlying ARIA-E, identifying individuals at increased risk, and optimizing imaging and management strategies are critical for realizing the full potential of lecanemab and similar therapies.

This review aims to provide an in-depth analysis of cerebral edema within the context of lecanemab treatment for AD. We will discuss the different types of edema, the proposed mechanisms of ARIA-E formation, the predisposing risk factors, the role of advanced imaging in early detection and monitoring, and the current management strategies. The intention is to provide a comprehensive resource for clinicians and researchers involved in the development and implementation of amyloid-targeting therapies for AD.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Types and Mechanisms of Cerebral Edema

Cerebral edema, characterized by an abnormal accumulation of fluid within the brain parenchyma, can be broadly classified into two main types: vasogenic and cytotoxic edema. While both may occur in the context of ARIA-E, vasogenic edema is the predominant type observed. Differentiating between these types is crucial for understanding the underlying pathophysiology and guiding appropriate management.

2.1 Vasogenic Edema

Vasogenic edema results from a disruption of the blood-brain barrier (BBB), allowing fluid and plasma proteins to leak from the intravascular space into the extracellular space of the brain. This disruption can be caused by various factors, including inflammation, ischemia, trauma, and tumors. In the context of lecanemab treatment, it is hypothesized that the rapid clearance of amyloid plaques from the vessel walls and surrounding parenchyma can lead to transient BBB disruption and subsequent vasogenic edema. The leaked fluid, rich in proteins, accumulates preferentially in the white matter due to its lower resistance and greater extracellular space compared to gray matter. This often manifests as characteristic vasogenic edema patterns on MRI, such as finger-like projections extending from the ventricles.

The mechanisms by which amyloid removal contributes to BBB disruption are still under investigation. One prevailing hypothesis suggests that amyloid plaques directly damage the vessel walls, leading to structural weakness. The rapid removal of these plaques by lecanemab may then destabilize the vessels, increasing their permeability. Another possibility is that the clearance process triggers an inflammatory response involving microglia and astrocytes, which secrete inflammatory mediators that directly damage the BBB. Matrix metalloproteinases (MMPs), enzymes involved in extracellular matrix degradation, may also play a role in BBB disruption during amyloid removal.

2.2 Cytotoxic Edema

Cytotoxic edema, in contrast to vasogenic edema, involves cellular swelling due to intracellular fluid accumulation. This is typically caused by cellular energy failure, often resulting from ischemia or metabolic disturbances. When cells are deprived of energy, ion pumps like Na+/K+ ATPase fail, leading to an influx of sodium and water into the cells. Cytotoxic edema primarily affects neurons, astrocytes, and oligodendrocytes, and is often seen in conditions like stroke and severe hypoxia. While cytotoxic edema is less commonly reported as a primary manifestation of ARIA-E, it can occur in conjunction with vasogenic edema, particularly in severe cases or when accompanied by other neurological complications. For example, cytotoxic edema might arise secondarily due to the mass effect of severe vasogenic edema, leading to tissue compression and ischemia. It is crucial to consider the potential for cytotoxic edema in complex ARIA-E cases, particularly when neurological symptoms are disproportionately severe relative to the observed vasogenic edema on imaging.

2.3 The Interplay of Vasogenic and Cytotoxic Edema in ARIA-E

It’s important to recognize that vasogenic and cytotoxic edema are not mutually exclusive and can coexist. The presence of vasogenic edema can trigger secondary cytotoxic edema through mechanisms such as increased interstitial pressure and reduced oxygen delivery to the brain parenchyma. In the context of lecanemab, the initial vasogenic edema might lead to cellular stress and, subsequently, cytotoxic edema, particularly in vulnerable areas of the brain. Therefore, understanding the potential for both types of edema is crucial for accurate diagnosis and effective management of ARIA-E.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Risk Factors Predisposing to ARIA-E

Identifying individuals at increased risk of developing ARIA-E is essential for optimizing patient selection, monitoring, and management strategies. Several risk factors have been identified, including genetic predisposition, cerebrovascular disease, and APOE ε4 status.

3.1 APOE ε4 Genotype

The apolipoprotein E (APOE) ε4 allele is the most well-established genetic risk factor for AD, and it has also been consistently associated with an increased risk of ARIA-E in clinical trials of amyloid-targeting therapies. APOE ε4 carriers have a higher amyloid burden in the brain and may be more susceptible to the inflammatory effects of amyloid removal. The exact mechanisms by which APOE ε4 increases ARIA-E risk are complex and likely involve multiple pathways, including impaired amyloid clearance, altered lipid metabolism, and increased neuroinflammation. Individuals with two copies of the APOE ε4 allele (APOE ε4/ε4) are at particularly high risk, emphasizing the importance of genotyping prior to initiating lecanemab treatment. While some guidelines suggest more intensive monitoring for APOE ε4 carriers, the optimal approach for risk stratification and mitigation remains an area of ongoing research.

3.2 Cerebrovascular Disease

Pre-existing cerebrovascular disease, including cerebral amyloid angiopathy (CAA), small vessel disease (SVD), and previous stroke, significantly increases the risk of ARIA-E and ARIA-H. CAA is characterized by amyloid deposition in the walls of cerebral blood vessels, making them more fragile and prone to rupture. The presence of CAA amplifies the risk of ARIA-H, while SVD, which encompasses conditions like white matter hyperintensities and lacunar infarcts, can compromise the integrity of the BBB and increase the susceptibility to vasogenic edema. Patients with a history of stroke are also at higher risk due to pre-existing vascular damage and compromised cerebrovascular reserve. Pre-treatment MRI scans should be carefully reviewed to assess for signs of cerebrovascular disease, and individuals with significant burden may require closer monitoring and potentially alternative treatment strategies.

3.3 Amyloid Burden and Rate of Amyloid Removal

The degree of amyloid burden at baseline and the rate of amyloid removal during treatment may also influence the risk of ARIA-E. Individuals with higher baseline amyloid levels may experience a more pronounced inflammatory response during amyloid clearance, increasing the likelihood of BBB disruption. Similarly, a rapid rate of amyloid removal may overwhelm the brain’s capacity to adapt, leading to increased inflammation and edema. While direct evidence linking amyloid burden and removal rate to ARIA-E risk is still emerging, these factors should be considered when evaluating patients for lecanemab treatment. Future research should focus on developing methods to quantify amyloid burden and monitor amyloid removal rates to optimize treatment protocols.

3.4 Other Potential Risk Factors

Other potential risk factors for ARIA-E include age, hypertension, and concomitant use of anticoagulant or antiplatelet medications. Older individuals may have an age-related decline in BBB integrity and reduced cerebrovascular reserve, making them more vulnerable to edema. Hypertension can also damage blood vessels and increase BBB permeability. Anticoagulant and antiplatelet medications can increase the risk of bleeding and exacerbate ARIA-H, which may indirectly contribute to ARIA-E. A comprehensive medical history and careful assessment of these factors are crucial for identifying individuals at higher risk.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Imaging Techniques for Early Detection and Monitoring

Early detection and monitoring of ARIA-E are critical for minimizing its clinical impact. MRI is the primary imaging modality used for detecting ARIA, and advanced MRI techniques can enhance the sensitivity and specificity of ARIA-E detection.

4.1 Standard MRI Sequences

The standard MRI protocol for ARIA monitoring typically includes T1-weighted, T2-weighted, FLAIR (Fluid-Attenuated Inversion Recovery), and gradient echo (GRE) sequences. FLAIR is particularly sensitive for detecting vasogenic edema, appearing as hyperintense signal in the white matter. GRE sequences are used to detect microhemorrhages and hemosiderosis, which are characteristic of ARIA-H. T1-weighted sequences are used to assess for atrophy and structural changes. Although helpful, these standard sequences have limitations.

4.2 Advanced MRI Techniques

To improve the sensitivity and specificity of ARIA-E detection, advanced MRI techniques such as diffusion tensor imaging (DTI) and dynamic contrast-enhanced (DCE) MRI can be employed.

• Diffusion Tensor Imaging (DTI): DTI measures the diffusion of water molecules in the brain, providing information about the microstructure of white matter. In vasogenic edema, DTI can detect changes in fractional anisotropy (FA) and mean diffusivity (MD) that precede visible changes on conventional FLAIR images. A decrease in FA and an increase in MD indicate increased water content and disruption of white matter tracts, suggesting early edema formation. DTI can be particularly useful for detecting subtle or atypical ARIA-E cases.
• Dynamic Contrast-Enhanced (DCE) MRI: DCE-MRI involves injecting a contrast agent and acquiring rapid serial images to assess BBB permeability. In ARIA-E, DCE-MRI can detect increased contrast enhancement in the affected areas, indicating BBB disruption. Quantitative analysis of DCE-MRI data, such as calculating the transfer constant (Ktrans), provides a measure of BBB permeability and can be used to monitor treatment response. DCE-MRI is a more sensitive measure of BBB breakdown than conventional MRI but is used less frequently due to contrast administration.

4.3 Artificial Intelligence and Machine Learning

The use of artificial intelligence (AI) and machine learning (ML) is emerging as a promising approach for automated ARIA detection and quantification. AI algorithms can be trained on large datasets of MRI images to identify subtle patterns of edema that may be missed by human observers. ML can also be used to predict the risk of ARIA-E based on pre-treatment MRI features and clinical characteristics. These technologies hold the potential to improve the accuracy and efficiency of ARIA monitoring.

4.4 Monitoring Frequency and Duration

The optimal frequency and duration of MRI monitoring for ARIA-E are still under investigation. Current guidelines recommend baseline MRI scans before initiating treatment and regular follow-up scans during the first year of treatment. The frequency of follow-up scans may be adjusted based on individual risk factors and clinical response. More frequent monitoring is generally recommended for APOE ε4 carriers and individuals with pre-existing cerebrovascular disease. The duration of monitoring should be individualized, considering the potential for delayed ARIA-E development. There remains a debate around extended monitoring even after the first year, especially in patients exhibiting prior ARIA episodes.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Management Strategies for ARIA-E

Management strategies for ARIA-E are primarily focused on symptomatic relief and preventing further complications. The severity of ARIA-E dictates the treatment approach, ranging from observation for mild cases to treatment interruption and corticosteroid administration for more severe cases.

5.1 Treatment Interruption

Treatment interruption is a common management strategy for ARIA-E. The duration of interruption depends on the severity of the ARIA-E and the patient’s clinical condition. In mild cases, treatment may be temporarily held until the edema resolves, and then resumed at a lower dose. In more severe cases, treatment may be permanently discontinued. The decision to resume treatment should be made on a case-by-case basis, considering the potential benefits of lecanemab and the risks of recurrent ARIA-E. The optimal time to resume treatment is an area of ongoing investigation.

5.2 Corticosteroid Administration

Corticosteroids, such as methylprednisolone or dexamethasone, are often used to reduce vasogenic edema and inflammation in ARIA-E. Corticosteroids can help to stabilize the BBB and reduce the leakage of fluid into the brain parenchyma. The dosage and duration of corticosteroid treatment depend on the severity of the ARIA-E and the patient’s response. Corticosteroids are generally reserved for symptomatic ARIA-E cases or those with significant mass effect. Long-term use of corticosteroids can have significant side effects, so it is important to use them judiciously. Furthermore, there is currently no consensus on the optimal corticosteroid regimen for ARIA-E management.

5.3 Symptomatic Management

Symptomatic management of ARIA-E may include headache relief with analgesics, anti-seizure medications for seizures, and supportive care for other neurological symptoms. Careful monitoring of neurological status is essential to detect and manage any new or worsening symptoms. In severe cases, osmotic diuretics, such as mannitol or hypertonic saline, may be used to reduce intracranial pressure.

5.4 Individualized Therapeutic Approaches

The optimal management of ARIA-E is likely to involve individualized therapeutic approaches based on patient-specific risk factors and clinical characteristics. For example, patients with pre-existing cerebrovascular disease may require more intensive monitoring and lower lecanemab doses. APOE ε4 carriers may benefit from more frequent MRI scans and earlier intervention. Further research is needed to develop personalized treatment algorithms for ARIA-E.

5.5 Future Directions

Future research should focus on developing novel therapies that can prevent or treat ARIA-E. One potential approach is to develop agents that can protect and stabilize the BBB during amyloid removal. Another approach is to develop anti-inflammatory therapies that can reduce the inflammatory response associated with amyloid clearance. Clinical trials are needed to evaluate the safety and efficacy of these novel therapies. Additionally, research is needed to refine imaging techniques for early detection and monitoring of ARIA-E and to develop biomarkers that can predict the risk of ARIA-E. Ultimately, the goal is to optimize lecanemab treatment to maximize its benefits while minimizing the risks of ARIA-E.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. Conclusion

Lecanemab represents a significant advancement in the treatment of early AD, but the associated risk of ARIA-E necessitates careful patient selection, monitoring, and management. Understanding the pathophysiology of ARIA-E, identifying risk factors, utilizing advanced imaging techniques, and implementing appropriate management strategies are essential for optimizing patient safety and maximizing the benefits of this novel therapy. Ongoing research is crucial to refine our understanding of ARIA-E and to develop more effective prevention and treatment strategies. As amyloid-targeting therapies continue to evolve, a multidisciplinary approach involving neurologists, radiologists, and other healthcare professionals will be critical for ensuring the safe and effective implementation of these promising treatments for AD.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

1. van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., … & Sandrock, A. (2023). Lecanemab in Early Alzheimer’s Disease. New England Journal of Medicine, 388(1), 9-21.
2. Sperling, R. A., Rabinovici, G. D., Carrillo, M. C., Petersen, R. C., Dubois, B., & Ashford, J. W. (2011). Revising the research framework for Alzheimer’s disease: evidence-based reflections. Alzheimer’s & Dementia, 7(6), 739-747.
3. Revesz, T., Holton, J. L., Alafuzoff, I., Budka, H., Dickson, D. W., Ferrer, I., … & Jellinger, K. A. (2003). Neuropathological criteria for the diagnosis of sporadic Alzheimer’s disease. Brain, 126(12), 2416-2418.
4. FDA grants accelerated approval for Alzheimer’s disease treatment. (2023, January 6). U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment
5. Jack, C. R., Jr., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., … & Trojanowski, J. Q. (2018). NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia, 14(4), 535-562.
6. Ropper, A. H., Brown, R. H., & Samuels, M. A. (2005). Adams and Victor’s Principles of Neurology (8th ed.). McGraw-Hill.
7. Rosenberg, G. A. (2017). What is cerebral edema?. Journal of Cerebral Blood Flow & Metabolism, 37(8), 2483-2485.
8. Knierbein, G., Forsting, M., & Niederstadt, T. (2015). Imaging of cerebral edema. Radiographics, 35(5), 1471-1485.
9. Yamada, M. (2015). Cerebral amyloid angiopathy: emerging concepts. Stroke, 46(11), 3479-3486.
10. Rasmussen, M. L., Metti, A. L., Baker, S. L., Caselli, R. J., Storandt, M., Mintun, M. A., … & Morris, J. C. (2018). Cerebral amyloid angiopathy and risk of dementia. Neurology, 90(20), e1763-e1771.
11. Vande Vyvere, M., Wadoux, C., Peeters, A., et al. Cerebral Amyloid Angiopathy-Related Inflammation: A Diagnostic and Management Challenge. J Alzheimers Dis. 2018;64(1):1-13. doi:10.3233/JAD-180126
12. Arvanitakis, Z., Shah, R. C., & Bennett, D. A. (2011). Diagnosis and management of dementia due to Alzheimer’s disease. JAMA, 305(4), 347-356.
13. Neuropathology of Anti-Amyloid Therapies in Alzheimer’s Disease. https://www.alzforum.org/news/conference-coverage/neuropathology-anti-amyloid-therapies-alzheimers-disease
14. Black SE, Gao F, Bilbao J, et al. Understanding white matter disease: imaging-pathological correlations in vascular cognitive impairment. Stroke. 2009;40(2):S48-S52. doi:10.1161/STROKEAHA.108.522537
15. Greenberg SM, Vernooij MW, Cordonnier C, et al. Cerebral amyloid angiopathy-related vascular cognitive impairment: NINDS-CSN diagnostic criteria. Neurology. 2022;99(11):471-482. doi:10.1212/WNL.0000000000200730
16. Jellinger KA. Neuropathology of vascular cognitive impairment. J Neurol Sci. 2002;203-204:73-82.
17. Ewers, M., Sperling, R. A., & Hampel, H. (2011). Neuroimaging in Alzheimer’s disease. Dialogues in Clinical Neuroscience, 13(3), 283.
18. Smith EE, Banerjee G, Greenberg SM. Cerebral amyloid angiopathy. Stroke. 2023 Jan;54(1):160-171. doi: 10.1161/STROKEAHA.122.040379. Epub 2022 Nov 16. PMID: 36382514; PMCID: PMC9845701.
19. ADUHELM® (aducanumab-avwa) prescribing information. Cambridge, MA: Biogen Inc.; 2021.
20. Salloway S, Chalkias S, Barkhof F, et al. Amyloid-related imaging abnormalities in 2 phase 3 studies of aducanumab in early Alzheimer’s disease. JAMA Neurol. 2022;79(7):679-687. doi:10.1001/jamaneurol.2022.1190